| Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review W Shalata, A Abu-Salman, R Steckbeck, B Mathew Jacob, I Massalha, ... Cancers 13 (20), 5218, 2021 | 73 | 2021 |
| Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study R Hadash-Bengad, E Hajaj, S Klein, S Merims, S Frank, G Eisenberg, ... Frontiers in oncology 10, 70, 2020 | 31 | 2020 |
| Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial MM Gounder, AA Razak, N Somaiah, S Chawla, J Martin-Broto, ... Journal of Clinical Oncology 40 (22), 2479, 2022 | 26 | 2022 |
| A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors W Shalata, S Weissmann, S Itzhaki Gabay, K Sheva, O Abu Saleh, ... Cancers 14 (21), 5451, 2022 | 15 | 2022 |
| Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy I Polishchuk, A Yakobson, M Zemel, A A Sharb, W Shalata, E Rosenberg, ... Immunotherapy 13 (10), 807-811, 2021 | 15 | 2021 |
| Associated Myocarditis: A Predictive Factor for Response? W Shalata, N Peled, I Gabizon, O Abu Saleh, W Kian, A Yakobson Case Reports in Oncology 13 (2), 550-557, 2020 | 14 | 2020 |
| Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis W Kian, M Zemel, F Elobra, AA Sharb, D Levitas, Y Assabag, F Alguayn, ... Anti-Cancer Drugs 33 (1), e738, 2022 | 13 | 2022 |
| Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study W Kian, M Zemel, EH Kestenbaum, K Rouvinov, W Alguayn, D Levitas, ... Medicine 101 (2), 2022 | 13 | 2022 |
| Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug D Perlstein, O Shlagman, Y Kogan, K Halevi-Tobias, A Yakobson, ... PLoS One 14 (12), e0226869, 2019 | 13 | 2019 |
| Crizotinib in MET exon 14-mutated or MET-amplified in advanced disease non-small cell lung cancer: A retrospective, single institution experience W Shalata, A Yakobson, S Weissmann, E Oscar, M Iraqi, W Kian, N Peled, ... Oncology 100 (9), 467-474, 2022 | 12 | 2022 |
| Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience W Shalata, J Zolnoorian, G Migliozzi, AA Jama, Y Dudnik, AY Cohen, ... International Journal of Molecular Sciences 24 (6), 5938, 2023 | 11 | 2023 |
| Vismodegib as first-line treatment of mutated sonic hedgehog pathway in adult medulloblastoma W Kian, LC Roisman, IM Goldstein, A Abo-Quider, B Samueli, N Wallach, ... JCO Precision Oncology 4, 2020 | 10 | 2020 |
| Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer W Kian, P Christopoulos, AA Remilah, E Levison, E Dudnik, W Shalata, ... Frontiers in Oncology 12, 1010311, 2022 | 9 | 2022 |
| Rapid response to the combination of lenvatinib and pembrolizumab in patients with advanced carcinomas (Lung adenocarcinoma and malignant pleural mesothelioma) W Shalata, M Iraqi, B Bhattacharya, V Fuchs, LC Roisman, AY Cohen, ... Cancers 13 (14), 3630, 2021 | 9 | 2021 |
| Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma K Rouvinov, K Nalbandyan, V Kozlov, N Peled, A Yakobson Case Reports in Oncology 12 (1), 29-32, 2019 | 8 | 2019 |
| Unexpected Adverse Events of Immune Checkpoint Inhibitors W Shalata, A Yakobson, AY Cohen, I Goldstein, OA Saleh, Y Dudnik, ... Life 13 (8), 1657, 2023 | 7 | 2023 |
| Novel biomarkers and therapeutic targets for melanoma N Sabag, A Yakobson, M Retchkiman, E Silberstein International Journal of Molecular Sciences 23 (19), 11656, 2022 | 7 | 2022 |
| Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel I Averbuch, R Stoff, M Miodovnik, S Fennig, G Bar‐Sela, A Yakobson, ... Cancer Medicine 12 (11), 12065-12070, 2023 | 6 | 2023 |
| PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma A Yakobson, A Abu Jama, O Abu Saleh, R Michlin, W Shalata Cancers 15 (16), 4041, 2023 | 5 | 2023 |
| Epithelioid hemangioendothelioma and epithelioid hemangioma: pazopanib as a potential salvage therapy A Yakobson, W Alguayn, W Shalata, D Levin, TA Kian, A Korngreen, ... Case Reports in Oncology 14 (1), 309-317, 2021 | 5 | 2021 |
